Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Tax Provisions: 2016-2024

Historic Tax Provisions for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Dec 2024 value amounting to $3.0 million.

  • Ultragenyx Pharmaceutical's Tax Provisions rose 188.12% to $873,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 314.91%. This contributed to the annual value of $3.0 million for FY2024, which is 262.68% up from last year.
  • According to the latest figures from FY2024, Ultragenyx Pharmaceutical's Tax Provisions is $3.0 million, which was up 262.68% from -$1.8 million recorded in FY2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Tax Provisions peaked at $7.3 million during FY2022, and registered a low of -$1.8 million during FY2023.
  • Moreover, its 3-year median value for Tax Provisions was $3.0 million (2024), whereas its average is $2.8 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Tax Provisions spiked by 602.68% in 2022 and then crashed by 124.88% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Tax Provisions (Yearly) stood at $1.2 million in 2020, then declined by 13.50% to $1.0 million in 2021, then soared by 602.68% to $7.3 million in 2022, then plummeted by 124.88% to -$1.8 million in 2023, then soared by 262.68% to $3.0 million in 2024.